PPARG and neoplasm: As a reaction towards thesafety-toxicological data collected in preclinical studies and clinical trialsregarding TZD use, the US Food and Drug Administration (FDA) (http://www.fda.gov/cder/present/DIA2004/15) issued a warning of tumor-related adverse effects of novelpotent PPARγ ligands that are currently in clinical trials as novel antidiabetics orobesity cures (reviewed in [82]) [83, 84].